Pause or continue? study tests ACE inhibitor timing to prevent kidney damage

NCT ID NCT07184918

Completed Knowledge-focused Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether continuing or temporarily stopping the blood pressure medicine Ramipril (an ACE inhibitor) before coronary angiography affects the risk of kidney injury from the contrast dye. 44 adults were randomly assigned to either keep taking their usual dose or stop it 48 hours before and restart 72 hours after the procedure. Researchers measured kidney function and injury markers to see which approach is safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ramipril (an ACE inhibitor)
What this could lead to: If it works, this could help doctors decide whether to pause ACE inhibitors before angiography to protect kidneys.
What could go wrong: This is a small, completed study with only 44 people, so results may not apply to everyone. It does not test a new treatment, just compares two approaches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY CONTRAST-INDUCED NEPHROPATHY CORONARY ANGIOGRAPHY

Contacts and locations

Locations

Faculty of Pharmacy Tanta university

Tanta, Gharbia Governorate, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.